{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:03:25Z","timestamp":1785528205080,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473161"],"award-info":[{"award-number":["82473161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangdong Science and Technology Department","award":["2024A1515011749"],"award-info":[{"award-number":["2024A1515011749"]}]},{"name":"Clinical Research Program of Nanfang Hospital, Southern Medical University","award":["2024CR008"],"award-info":[{"award-number":["2024CR008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s11060-026-05690-5","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:24:33Z","timestamp":1782969873000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical, surgical, and molecular characteristics and outcomes of adult patients with diffuse midline glioma, H3 K27-altered, treated with surgical resection"],"prefix":"10.1007","volume":"178","author":[{"given":"Jinfeng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanqiang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-zhong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"3","key":"5690_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00401-023-02609-6","volume":"146","author":"EA Williams","year":"2023","unstructured":"Williams EA et al (2023) A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Acta Neuropathol 146(3):515\u2013525","journal-title":"Acta Neuropathol"},{"key":"5690_CR2","doi-asserted-by":"crossref","unstructured":"Jones C et al (2016) Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology","DOI":"10.1093\/neuonc\/now101"},{"issue":"3","key":"5690_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","volume":"124","author":"D-A Khuong-Quang","year":"2012","unstructured":"Khuong-Quang D-A et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124(3):439\u2013447","journal-title":"Acta Neuropathol"},{"issue":"Suppl 5","key":"5690_CR4","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT et al (2019) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012\u20132016. Neuro Oncol 21(Suppl 5):v1\u2013v100","journal-title":"Neuro Oncol"},{"issue":"3","key":"5690_CR5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11060-022-04024-5","volume":"158","author":"CA Lopez-Perez","year":"2022","unstructured":"Lopez-Perez CA et al (2022) Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity. J Neurooncol 158(3):369\u2013378","journal-title":"J Neurooncol"},{"issue":"5","key":"5690_CR6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.3171\/2024.8.JNS241180","volume":"142","author":"Y Sim","year":"2025","unstructured":"Sim Y et al (2025) A comprehensive multicenter analysis of clinical, molecular, and imaging characteristics and outcomes of H3 K27-altered diffuse midline glioma in adults. J Neurosurg 142(5):1307\u20131318","journal-title":"J Neurosurg"},{"issue":"1","key":"5690_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccell.2023.11.002","volume":"42","author":"C Koschmann","year":"2024","unstructured":"Koschmann C et al (2024) A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell 42(1):1\u20135","journal-title":"Cancer Cell"},{"issue":"1","key":"5690_CR8","first-page":"vdae155","volume":"6","author":"JN Baugh","year":"2024","unstructured":"Baugh JN et al (2024) Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG\/DMG Registry. Neurooncol Adv 6(1):vdae155","journal-title":"Neurooncol Adv"},{"issue":"9","key":"5690_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","volume":"24","author":"ML Persson","year":"2022","unstructured":"Persson ML et al (2022) The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol 24(9):1408\u20131422","journal-title":"Neuro Oncol"},{"issue":"5","key":"5690_CR10","first-page":"940","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia P et al (2023) Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neurooncology 25(5):940\u2013954","journal-title":"Neurooncology"},{"key":"5690_CR11","doi-asserted-by":"crossref","unstructured":"Blakeley J et al (2025) Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline rapid recommendation update. Neuro Oncol","DOI":"10.1200\/GDL.25.0429"},{"issue":"4","key":"5690_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.21.02036","volume":"40","author":"NA Mohile","year":"2022","unstructured":"Mohile NA et al (2022) Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. J Clin Oncol 40(4):403\u2013426","journal-title":"J Clin Oncol"},{"issue":"8","key":"5690_CR13","first-page":"1231","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neurooncology 23(8):1231\u20131251","journal-title":"Neurooncology"},{"issue":"1","key":"5690_CR14","first-page":"166","volume":"26","author":"P Karschnia","year":"2024","unstructured":"Karschnia P et al (2024) Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group. Neurooncology 26(1):166\u2013177","journal-title":"Neurooncology"},{"issue":"10","key":"5690_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"10","key":"5690_CR16","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997\u20131003","journal-title":"N Engl J Med"},{"key":"5690_CR17","doi-asserted-by":"crossref","unstructured":"Solomon DA et al (2016) Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 569\u2013580","DOI":"10.1111\/bpa.12336"},{"key":"5690_CR18","doi-asserted-by":"crossref","unstructured":"Aihara K et al (2014) H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol:140\u2013146","DOI":"10.1093\/neuonc\/not144"},{"issue":"4","key":"5690_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay A et al (2017) Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell 32(4):520\u2013537e5","journal-title":"Cancer Cell"},{"issue":"4","key":"5690_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41388-021-02102-y","volume":"41","author":"IJ Findlay","year":"2022","unstructured":"Findlay IJ et al (2022) Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies. Oncogene 41(4):461\u2013475","journal-title":"Oncogene"},{"issue":"1","key":"5690_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11060-019-03134-x","volume":"143","author":"KC Schreck","year":"2019","unstructured":"Schreck KC et al (2019) Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 143(1):87\u201393","journal-title":"J Neurooncol"},{"issue":"1","key":"5690_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41392-025-02299-4","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh S et al (2025) Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther 10(1):213","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"5690_CR23","doi-asserted-by":"publisher","first-page":"e2226551","DOI":"10.1001\/jamanetworkopen.2022.26551","volume":"5","author":"R Hatoum","year":"2022","unstructured":"Hatoum R et al (2022) Extent of Tumor Resection and Survival in Pediatric Patients With High-Grade Gliomas: A Systematic Review and Meta-analysis. JAMA Netw Open 5(8):e2226551","journal-title":"JAMA Netw Open"},{"key":"5690_CR24","doi-asserted-by":"crossref","unstructured":"Ryba A et al (2024) Insights from a multicenter study on adult H3 K27M-mutated glioma: surgical resection\u2019s limited influence on overall survival, ATRX as molecular prognosticator. Neuro Oncol:1479\u20131493","DOI":"10.1093\/neuonc\/noae061"},{"issue":"4","key":"5690_CR25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1245\/s10434-013-3380-0","volume":"21","author":"X Wang","year":"2014","unstructured":"Wang X et al (2014) Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. Ann Surg Oncol 21(4):1337\u20131344","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"5690_CR26","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1158\/1078-0432.CCR-07-1719","volume":"14","author":"JN Sarkaria","year":"2008","unstructured":"Sarkaria JN et al (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14(10):2900\u20132908","journal-title":"Clin Cancer Res"},{"key":"5690_CR27","doi-asserted-by":"publisher","first-page":"103453","DOI":"10.1016\/j.ebiom.2021.103453","volume":"69","author":"G Price","year":"2021","unstructured":"Price G et al (2021) Current knowledge on the immune microenvironment and emerging immunotherapies in diffuse midline glioma. EBioMedicine 69:103453","journal-title":"EBioMedicine"},{"key":"5690_CR28","doi-asserted-by":"crossref","unstructured":"Voloshin T et al (2020) Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother:1191\u20131204","DOI":"10.1007\/s00262-020-02534-7"},{"key":"5690_CR29","doi-asserted-by":"crossref","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15:325\u2013340","DOI":"10.1038\/nrclinonc.2018.29"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05690-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05690-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05690-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:18:27Z","timestamp":1785521907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05690-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5690"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05690-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and the Institutional Review Board of Nanfang Hospital, Southern Medical University, approved this study (Ethical Review No. NFEC-202508-K27-01), with patient consent requirements waived due to the retrospective design.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"85"}}